AztraZeneca Struggling as Generic Seroquel Gets the Green Light

0
90

With a U.S. judge refusing to grant an injunction against generic versions of it’s top-selling drug Seroquel last Friday, the Wall Street Journal reports that AstraZeneca is struggling to control costs and find acquisitions that will help it to exploit new product lines. The decision follows the U.K. High Court’s decision last week that AstraZeneca’s patent on Seroquel is invalid in Britain.

Article → 

***

Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.

Previous articleDyskinesia, Dissociation, and the Long Term Consequences of “Antipsychotic” Drugs
Next articleSecond-Generation Antipsychotics Just as Likely as Older Drugs to Cause EPS
Kermit Cole
Kermit Cole, MFT, founding editor of Mad in America, works in Santa Fe, New Mexico as a couples and family therapist. Inspired by Open Dialogue, he works as part of a team and consults with couples and families that have members identified as patients. His work in residential treatment — largely with severely traumatized and/or "psychotic" clients — led to an appreciation of the power and beauty of systemic philosophy and practice, as the alternative to the prevailing focus on individual pathology. A former film-maker, he has undergraduate and master's degrees in psychology from Harvard University, as well as an MFT degree from the Council for Relationships in Philadelphia. He is a doctoral candidate with the Taos Institute and the Free University of Brussels. You can reach him at [email protected]